Skip to content

Type 1 diabetes — hypoglycemia

TL;DR — Hypoglycemia remains the immediate limiting toxicity of insulin. Recurrent lows blunt autonomic warning and counterregulation, producing hypoglycemia-associated autonomic failure; impaired awareness concentrates severe-event risk (Rickels 2019, PMID 31389033). CGM and AID reduce biochemical hypoglycemia, but severe events persist and require structured avoidance, education, and ready-to-use glucagon (Brown 2019, PMID 31618560; Ali 2023, PMID 36645139). Dasiglucagon and nasal glucagon provide effective non-reconstitution rescue options, while recurrent unexplained severe episodes should trigger systematic review rather than simple target relaxation (Pieber 2021, PMID 35239971; Matsuhisa 2020, PMID 32115879).

Definitions and consequence

Level Glucose Meaning
Alert <70 mg/dL (<3.9 mmol/L) Action threshold
Clinically important <54 mg/dL (<3.0 mmol/L) Neurogenic/neuroglycopenic risk
Severe No glucose threshold Cognitive impairment requiring another person

Severe hypoglycemia is defined by assistance, not a meter number. Seizure, coma, trauma, arrhythmia, and death are possible; less dramatic episodes disrupt sleep, work, learning, exercise, and driving.

Counterregulatory failure

In T1D, loss of intra-islet insulin signaling impairs glucagon response; antecedent hypoglycemia and exercise can lower the sympathoadrenal threshold. Recurrent exposure therefore both results from and worsens defective awareness (Rickels 2019, PMID 31389033).

Risk amplifier Mechanism or marker Modifiable lever
Prior severe event Strong recurrence marker Structured review and avoidance
Impaired awareness Warning arrives late/absent Avoid lows; education; technology
Sleep Blunted detection and response Predictive suspend/AID, alarms
Exercise Higher uptake and delayed sensitivity Insulin/carbohydrate plan
Alcohol Inhibits hepatic glucose output Education and overnight plan
Renal impairment Reduced insulin clearance Dose adjustment
Infancy/older age Reliance on carers; variable symptoms Individualized targets and sharing

T1D Exchange reported both severe hypoglycemia and DKA in youth, showing that avoiding one extreme cannot rely on accepting the other (Cengiz 2013, PMID 23469984).

Awareness assessment and restoration

Validated questionnaires identify impaired awareness, but discordance between scores and CGM is possible. Prevalence appears to have fallen in the CGM era, yet high-risk subgroups remain (Ali 2023, PMID 36645139; Zammitt 2025, PMID 40386839).

HARPdoc compared a cognition-focused program with blood-glucose-awareness training in adults with persistent problematic hypoglycemia. Both structured pathways reduced severe events; HARPdoc did not outperform the comparator on the primary severe-hypoglycemia endpoint, but addressed maladaptive beliefs (Amiel 2022, PMID 35484106; NCT02940873).

Prevention hierarchy

  1. Identify timing, insulin-on-board, exercise, alcohol, renal function, meal and device contributors.
  2. Set CGM alerts and review time <70 and <54 mg/dL.
  3. Adjust basal, bolus timing, ratios and correction factors.
  4. Use structured education and deliberate hypoglycemia avoidance.
  5. Escalate to predictive suspend or AID where accessible.
  6. For persistent severe events, refer to a specialist pathway and consider transplant evaluation in exceptional cases.

Closed-loop reduced time below 70 mg/dL by 0.88 percentage points (95% CI 0.57–1.19) versus sensor-augmented pump in iDCL (Brown 2019, PMID 31618560). This sensor endpoint is valuable but does not prove elimination of rare severe events.

Rescue glucagon

Form Preparation Use case Evidence/limitation
Reconstituted injection Mix immediately Established rescue Multistep under stress
Nasal powder Ready to administer Needle-free caregiver rescue Nasal adverse effects; randomized crossover evidence (Matsuhisa 2020, PMID 32115879)
Stable autoinjector/prefilled Ready to inject Rapid caregiver use Cost and availability
Dasiglucagon Stable analog injection Severe rescue Phase 3 randomized evidence (Pieber 2021, PMID 35239971)
Mini-dose glucagon Small non-severe doses Exercise/illness protocols Product- and protocol-specific evidence

Rescuers need training before an emergency. After glucagon, recurrence can occur because the underlying insulin exposure persists.

Fear of hypoglycemia

Fear is rational when anchored in prior events but can drive chronic hyperglycemia, avoidance of activity, sleep disruption, and family surveillance. A systematic review found effects across type 1 and type 2 diabetes and substantial measurement heterogeneity (Zhang 2020, PMID 33091198). AID may reduce distress in users and caregivers, but benefit varies (Canha 2025, PMID 39726162).

Contemporary prevalence is lower, not zero

In 782 adults, 89% using CGM, 21% had impaired awareness by Gold score and 5.3% reported recent severe hypoglycemia. Severe-event odds rose with glucose coefficient of variation (OR 1.14 per percentage point), anxiety screen (OR 3.0), and a symptom threshold <3.0 mmol/L (OR 6.7); deprivation, depression, and female sex predicted impaired awareness (Zammitt 2025, PMID 40386839).

Cohort Technology context IAH/severe-event result Caveat
UK adults, n=782 89% CGM IAH 21%; recent severe event 5.3% Cross-sectional self-report
T1D Exchange adults, n=1,580 94% CGM; 69% HCL IAH associated with 88% higher severe-event odds 30% reported a severe event in six months
US follow-up, n=1,056 94.4% CGM; rising AID ~30% IAH and ~20% annual severe events 97% White; 53% response
Youth population cohorts Contemporary care IAH 15.9%; 0.92 severe events/100 patient-years Cross-era management differs

The adult findings appear discordant because instruments, recall windows, sampling, and event definitions differ. A brief HypoA-Q performed comparably to Gold and Clarke-derived measures and linked IAH to twofold odds of ≥1% time <54 mg/dL (Lin 2025, PMID 39477881). A separate US follow-up found persistent high burden despite near-universal CGM (Sherr 2026, PMID 41747141), while youth data documented a 30-fold fall in severe-event rate since 2002 (Delaney 2026, PMID 42138725).

Avoidance can partially reverse physiology

HypoCOMPaSS randomized 96 adults with mean 29-year duration in a 2×2 pump-versus-injection and CGM-versus-SMBG design, while every group received equivalent hypoglycemia-focused education. Time ≤3.0 mmol/L fell from 53 to 24 minutes/day, Gold score from 5.1 to 4.1, and severe events from 8.9 to 0.8/person-year, without HbA1c deterioration; device-group differences were not significant (Little 2014, PMID 24854041).

At 24 months, severe events remained 0.4/person-year versus 8.9 before intervention and HbA1c improved from 8.2% to 7.7% (Little 2018, PMID 29661916). Clamp testing in 18 participants shifted first perceived symptoms from 2.6 to 3.1 mmol/L and increased symptom/metanephrine responses, while the cognitive-decline threshold did not change (Leelarathna 2013, PMID 24130355). Awareness restoration is therefore partial and multidimensional.

Who remains at risk after optimized care?

Among 71 HypoCOMPaSS participants with prior severe events, 39% continued events over two years at 1.5±1.0/person-year. Incomplete response correlated with baseline event rate (16.9 vs 6.4/person-year), fear, persistent awareness impairment, and peripheral neuropathy (39% vs 4.7%) (Flatt 2020, PMID 31484666). These variables can identify escalation needs but do not yet prescribe which next therapy will work.

HARPdoc and BGAT both reduced median severe events from 5/person-year at baseline to 1 at 12 months and 0 at 24 months. HARPdoc was not superior for events (IRR 1.25, 95% CI 0.51–3.09 at 12 months), but improved unhelpful cognitions, distress, depression, and anxiety relative to BGAT (Amiel 2022, PMID 35484106). A negative superiority result does not mean psychoeducation was ineffective; the active comparator also worked.

Residual insulin secretion changes risk

After mean 35-year T1D duration, severe-event history was 27% with peak C-peptide >0.2 nmol/L and 48% with 0.03–0.2, versus 74% with only 0.003–0.03 and 70% with none (Gubitosi-Klug 2021, PMID 33529168). This supports a biological contribution of endogenous insulin, but does not justify transplantation solely to raise C-peptide without weighing immunosuppression.

Fear, detection, and behavior

Technology reduced the worry subscale modestly in randomized studies: standardized mean difference −0.14 (95% CI −0.23 to −0.05) for real-time CGM and −0.17 (−0.33 to −0.01) for AID (Talbo 2023, PMID 37593226). Severe hypoglycemia consistently relates to fear and distress, but associations with broader quality-of-life domains are mixed (Chatwin 2021, PMID 33722700).

Exercise adds a detection hazard. In 17 adults, CGM lagged the blood-glucose fall by 12±11 minutes and MARD rose to 13% during aerobic activity (Zaharieva 2019, PMID 31059282). When symptoms and sensor disagree during a rapid fall, confirmation is a safety behavior rather than a rejection of CGM.

Mortality attribution requires caution

A Swedish incident-diabetes cohort recorded seven deaths with hypoglycemia present among 58 deaths over 21,001 person-years; social/mental dysfunction or alcohol/drug misuse appeared in 40 deaths, and only one was unexplained “dead in bed” (Wibell 2001, PMID 11285046). This does not make hypoglycemia harmless; it shows that causal attribution after an unwitnessed death is uncertain and coexisting vulnerabilities matter.

Open questions

  • Which CGM-derived pattern best predicts the next severe event beyond prior history? (Zammitt 2025, PMID 40386839)
  • How long must strict avoidance last to restore awareness, and who does not recover? (Rickels 2019, PMID 31389033)
  • Do ready-to-use glucagon products improve real-world treatment completion and outcomes rather than simulated success? (Pieber 2021, PMID 35239971)
  • Which psychological intervention best treats fear without accepting excess hyperglycemia? (Zhang 2020, PMID 33091198)

References

  1. Rickels MR. Hypoglycemia-associated autonomic failure and therapeutic options. Ann N Y Acad Sci. 2019;1454:68-79. PMID 31389033
  2. Cengiz E, et al. Severe hypoglycemia and diabetic ketoacidosis among youth in T1D Exchange. Pediatr Diabetes. 2013;14:447-454. PMID 23469984
  3. Brown SA, et al. Six-Month Randomized Trial of Closed-Loop Control. N Engl J Med. 2019;381:1707-1717. PMID 31618560
  4. Ali N, et al. Fall in prevalence of impaired awareness of hypoglycaemia. Diabet Med. 2023. PMID 36645139
  5. Zammitt NN, et al. Predictors of impaired awareness and severe hypoglycaemia. Diabet Med. 2025. PMID 40386839
  6. Amiel SA, et al. Hypoglycaemia Awareness Restoration Programme randomized trial. Nat Commun. 2022;13:2229. PMID 35484106
  7. Pieber TR, et al. Dasiglucagon for Severe Hypoglycemia. Diabetes Care. 2021;44:1361-1367. PMID 35239971
  8. Matsuhisa M, et al. Nasal glucagon for insulin-induced hypoglycaemia. Diabetes Obes Metab. 2020;22:1167-1175. PMID 32115879
  9. Zhang Y, et al. Fear of hypoglycemia: a systematic review. J Clin Nurs. 2020. PMID 33091198
  10. Canha D, et al. AID use and diabetes distress in people with T1D and caregivers. Diabet Med. 2025. PMID 39726162
  11. Lin YK, et al. Characterising impaired awareness and associated risks through HypoA-Q. Diabetologia. 2025;68:433-443. PMID 39477881
  12. Sherr JL, et al. Persistent Burden of Severe Hypoglycemia and Impaired Awareness Despite Technology Use. Diabetes Care. 2026;49:650-657. PMID 41747141
  13. Delaney PWJ, et al. Reduced Prevalence of Impaired Awareness Over Two Decades in Youth. Diabetes Care. 2026;49:1280-1284. PMID 42138725
  14. Little SA, et al. Recovery of hypoglycemia awareness: HypoCOMPaSS randomized trial. Diabetes Care. 2014;37:2114-2122. PMID 24854041
  15. Little SA, et al. Sustained Reduction in Severe Hypoglycemia: Two-Year HypoCOMPaSS Follow-up. Diabetes Care. 2018;41:1600-1607. PMID 29661916
  16. Leelarathna L, et al. Restoration of self-awareness of hypoglycemia: HypoCOMPaSS clamp substudy. Diabetes Care. 2013;36:4063-4070. PMID 24130355
  17. Flatt AJS, et al. Predictors of Recurrent Severe Hypoglycemia During HypoCOMPaSS. Diabetes Care. 2020;43:44-52. PMID 31484666
  18. Gubitosi-Klug RA, et al. Residual β cell function in long-term type 1 diabetes and hypoglycemia. J Clin Invest. 2021;131. PMID 33529168
  19. Talbo MK, et al. Effect of diabetes technologies on fear of hypoglycaemia. EClinicalMedicine. 2023;62:102119. PMID 37593226
  20. Chatwin H, et al. The impact of hypoglycaemia on quality of life in adults with type 1 diabetes. Diabetes Res Clin Pract. 2021;174:108752. PMID 33722700
  21. Zaharieva DP, et al. CGM Lag Time During Aerobic Exercise in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2019;21:313-321. PMID 31059282
  22. Wibell L, et al. Increased mortality in diabetes during the first 10 years. J Intern Med. 2001;249:263-270. PMID 11285046
  23. McNeilly AD, McCrimmon RJ. Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab. Diabetologia. 2018;61:743-750. PMID 29417183
  24. Dagogo-Jack S. Hypoglycemia in type 1 diabetes mellitus: pathophysiology and prevention. Treat Endocrinol. 2004;3:91-103. PMID 15743105
  25. Hendrieckx C, et al. Severe hypoglycemia, impaired awareness, and self-monitoring in adults. J Diabetes Complications. 2017;31:577-582. PMID 27993524